Effect of Tofogliflozin on Body Composition and Glycemic Control in Japanese Subjects with Type 2 Diabetes Mellitus

Autor: Tomohiko Kimura, Masashi Shimoda, Kohei Kaku, Shinji Kamei, Masahiro Iwamoto, Hideaki Kaneto, Tomoatsu Mune, Tomoe Kinoshita, Hidenori Hirukawa, Shuhei Nakanishi, Fuminori Tatsumi, Miyuki Kameyama, Kenji Kohara, Atsushi Obata
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Blood Glucose
Male
medicine.medical_specialty
endocrine system diseases
Article Subject
Endocrinology
Diabetes and Metabolism
030209 endocrinology & metabolism
030204 cardiovascular system & hematology
lcsh:Diseases of the endocrine glands. Clinical endocrinology
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Endocrinology
Asian People
Glucosides
Japan
Diabetes mellitus
Internal medicine
Electric Impedance
medicine
Humans
Benzhydryl Compounds
Retrospective Studies
Glycemic
Univariate analysis
lcsh:RC648-665
business.industry
Type 2 Diabetes Mellitus
Skeletal muscle
nutritional and metabolic diseases
Retrospective cohort study
Middle Aged
medicine.disease
medicine.anatomical_structure
Diabetes Mellitus
Type 2
chemistry
Sarcopenia
Body Composition
Female
business
Tofogliflozin
Research Article
Zdroj: Journal of Diabetes Research, Vol 2018 (2018)
Journal of Diabetes Research
ISSN: 2314-6745
DOI: 10.1155/2018/6470137
Popis: Sodium-glucose cotransporter 2 inhibitor tofogliflozin is a new type of antidiabetic drug for individuals with type 2 diabetes mellitus (T2DM). The aim of this study was to examine in which type of individuals and/or under which conditions tofogliflozin could exert more beneficial effects on body composition and/or glycemic control in Japanese individuals with T2DM. We retrospectively evaluated the effects of tofogliflozin on body composition and/or glycemic control in individuals with T2DM who newly started taking tofogliflozin. After tofogliflozin treatment, body weight was significantly reduced and HbA1c levels were significantly decreased. Body fat mass, skeletal muscle mass, and skeletal muscle index, a marker for sarcopenia, were also reduced after the treatment. In univariate analyses, there was a statistically significant association between the decrease of HbA1c level after tofogliflozin treatment (Δ HbA1c) and the following parameters such as HbA1c levels at baseline, visceral fat area (VFA) at baseline, and reduction of VFA after the treatment (Δ VFA). Furthermore, in multivariate analyses, HbA1c levels at baseline and duration of diabetes were independently associated with Δ HbA1c. These results suggest that tofogliflozin would be more suitable for relatively obese individuals whose duration of diabetes is relatively short.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje